SQI Diagnostics (TSXV:SQD) - Aktienkurs, Nachrichten und Analyse

SQD Aktienübersicht

SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide.

Über das Unternehmen

SQD grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	1/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 20.5% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung (CA$6M)

Negatives Eigenkapital

Aktien sind hochgradig illiquide

+ 3 mehr Risiken

SQI Diagnostics Inc. Wettbewerber

Evome Medical Technologies

TSXV:EVMT

CA$7.6m

Scryb

CNSX:SCYB

CA$7.3m

Perimeter Medical Imaging AI

TSXV:PINK

CA$25.4m

Frequency Exchange

TSXV:FREQ

CA$4.7m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für SQI Diagnostics
Historische Aktienkurse
Aktueller Aktienkurs	CA$0.015
52-Wochen-Hoch	CA$0.17
52-Wochen-Tief	CA$0.01
Beta	0.075
11 Monat Veränderung	0%
3 Monate Veränderung	0%
1 Jahr Veränderung	-85.71%
33 Jahre Veränderung	-93.88%
5 Jahre Veränderung	-89.29%
Veränderung seit IPO	-99.23%

Aktuelle Nachrichten und Updates

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

Aktionärsrenditen

	SQD	CA Medical Equipment	CA Markt
7D	0%	-2.0%	1.4%
1Y	-85.7%	-31.3%	8.4%

Rendite im Vergleich zur Industrie: SQD unter dem Niveau der Branche Canadian Medical Equipment, die im vergangenen Jahr eine Rendite von -27.7% erzielte.

Rendite vs. Markt: SQD hinter dem Markt Canadian zurück, der im vergangenen Jahr eine Rendite von 12.4 erzielte.

Preisvolatilität

Is SQD's price volatile compared to industry and market?
SQD volatility
SQD Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	9.5%
Market Average Movement	8.2%
10% most volatile stocks in CA Market	16.7%
10% least volatile stocks in CA Market	3.0%

Stabiler Aktienkurs: SQDDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: [Unzureichende Daten]], um die Volatilitätsveränderung von SQD im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1999	n/a	Andrew Morris	www.sqidiagnostics.com

SQI Diagnostics Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von SQI Diagnostics im Vergleich zum Marktanteil des Unternehmens?
SQD grundlegende Statistiken
Marktanteil	CA$6.11m
Gewinn(TTM)	-CA$19.14m
Umsatz(TTM)	CA$3.05m

2.0x

Kurs-Umsatz-Verhältnis

-0.3x

Kurs-Gewinn-Verhältnis

Ist SQD zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
SQD Gewinn- und Verlustrechnung (TTM)
Einnahmen	CA$3.05m
Kosten der Einnahmen	CA$3.19m
Bruttogewinn	-CA$140.00k
Sonstige Ausgaben	CA$19.00m
Umsatz	-CA$19.14m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.047
Bruttomarge	-4.60%
Nettogewinnspanne	-628.51%
Schulden/Eigenkapital-Verhältnis	-103.3%

Wie hat sich SQD auf lange Sicht entwickelt?

Historische Performance und Vergleiche

SQD Aktienübersicht

Belohnungen

Risikoanalyse

SQI Diagnostics Inc. Wettbewerber

TSXV:EVMT

CA$7.6m

CNSX:SCYB

CA$7.3m

TSXV:PINK

CA$25.4m

TSXV:FREQ

CA$4.7m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Recent updates

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

SQI Diagnostics Inc.'s Grundlagenzusammenfassung

2.0x

-0.3x

Erträge &amp; Einnahmen

Erträge & Einnahmen